› 4oef

X-ray diffraction
1.8Å resolution

Crystal Structure Analysis of FGF2-Disaccharide (S6I2) complex

Released:
DOI: 10.2210/pdb4oef/pdb
PDB entry 4oef coloured by chain, front view.
PDB entry 4oef coloured by chain, side view.
PDB entry 4oef coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Interactions that influence the binding of synthetic heparan sulfate based disaccharides to fibroblast growth factor-2.
Li YC, Ho IH, Ku CC, Zhong YQ, Hu YP, Chen ZG, Chen CY, Lin WC, Zulueta MM, Hung SC, Lin MG, Wang CC, Hsiao CD
ACS Chem Biol 9 1712-7 (2014)
PMID: 24959968

Function and Biology Details

Biochemical function:
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-140533 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecules (2 distinct):
Fibroblast growth factor 2 Chain: A
Molecule details ›
Chain: A
Length: 155 amino acids
Theoretical weight: 17.25 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli BL21
UniProt:
  • Canonical: P09038 (Residues: 134-288; Coverage: 54%)
Gene names: FGF2, FGFB
Sequence domains: Fibroblast growth factor
Structure domains: Trefoil (Acidic Fibroblast Growth Factor, subunit A)

Ligands and Environments

Carbohydrate polymer : NEW Components: IDY, SGN
Carbohydrate polymer
No bound ligands
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: RIGAKU FR-E+ SUPERBRIGHT
Spacegroup: P1
Unit cell:
a: 30.417Å b: 33.083Å c: 35.608Å
α: 65.52° β: 72.6° γ: 77.35°
R-values:
R R work R free
0.174 0.169 0.22
Expression system: Escherichia coli BL21

Quick links

Citations

2 review citations

Heparin-Mimicking Polymers: Synthesis and Biological Applications.
Paluck et al. (2016)
1 more

1 mention without citation

A Comparative Study of Systems Pharmacology and Gene Chip Technology for Predicting Targets of a Traditional Chinese Medicine Formula in Primary Liver Cancer Treatment.
Li et al. (2022)